Terms: = Kidney tumors AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Clinical Outcome
3 results:
1. Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.
Roumenina LT; Daugan MV; Noé R; Petitprez F; Vano YA; Sanchez-Salas R; Becht E; Meilleroux J; Clec'h BL; Giraldo NA; Merle NS; Sun CM; Verkarre V; Validire P; Selves J; Lacroix L; Delfour O; Vandenberghe I; Thuilliez C; Keddani S; Sakhi IB; Barret E; Ferré P; Corvaïa N; Passioukov A; Chetaille E; Botto M; de Reynies A; Oudard SM; Mejean A; Cathelineau X; Sautès-Fridman C; Fridman WH
Cancer Immunol Res; 2019 Jul; 7(7):1091-1105. PubMed ID: 31164356
[TBL] [Abstract] [Full Text] [Related]
2. Immune infiltration in renal cell carcinoma.
Zhang S; Zhang E; Long J; Hu Z; Peng J; Liu L; Tang F; Li L; Ouyang Y; Zeng Z
Cancer Sci; 2019 May; 110(5):1564-1572. PubMed ID: 30861269
[TBL] [Abstract] [Full Text] [Related]
3. The Association Between PD-L1 Expression and the clinical outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract] [Full Text] [Related]
